Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has proven effective in adult T-cell leukemia/ lymphoma (ATL) patients. To study the graft-versus-ATL (Gv-ATL) effects after allo-HSCT, we analyzed 21 ATL patients who had been treated at our hospital. Of these, 18 had acute-, 2 had lymphoma-and 1 had chronic-type ATL; at allo-HSCT, seven patients were in CR, one was in PR, five had stable disease (SD) and eight had progressive disease (PD). Disease state after allo-HSCT was CR in 14, PR in 3, SD in 1 and PD in 3 patients. Among 15 patients who survived longer than 100 days, ATL relapsed in 10 patients, skin relapsed in 9 patients and 5 had relapsed on the skin alone. After we discontinued immunosuppressant therapy in these 10 patients, 8 manifested GVHD; ATL was ameliorated to CR in 6 patients. Donor lymphocytes were infused into two patients who did not show GVHD; one obtained CR. In five patients with skin relapse alone, four patients achieved CR following the discontinuation of the immunosuppressants. Our results demonstrate that relapse of ATL after allo-HSCT tends to develop on skin, and Gv-ATL effects played a critical role in the outcome of allo-HSCT for ATL.
Introduction
Adult T-cell leukemia/lymphoma (ATL), one of the most aggressive hematological malignancies, is caused by a specific retrovirus, human T-cell lymphotropic virus type I (HTLV-1). It is endemic in southwestern Japan where our institutes are located. ATL manifests systemic symptoms such as lymph node swelling, hepatosplenomegaly, abnormal peripheral blood lymphocytes with lobulated nuclei, the so-called flower cells, hypercalcemia and skin lesions that are seen in about 50% of ATL patients. [1] [2] [3] As the results of therapeutic trials using different combination chemotherapies to improve the poor prognosis of ATL are unsatisfactory, 4, 5 an alternative therapeutic approach, hematopoietic stem cell transplantation (HSCT), has been tried. Although many ATL patients treated by autologous HSCT experienced recurrence, 6 a better therapeutic outcome was obtained with allogeneic HSCT. [7] [8] [9] [10] As allo-HSCT may induce GVHD by eliciting cellular immune responses of donor against recipient cells, graft-versus-ATL (Gv-ATL) effects may play a beneficial role. To assess whether Gv-ATL effects after allo-HSCT contribute to the eradication of ATL cells, we performed a retrospective study of 21 ATL patients who had undergone allo-HSCT.
Patients and methods

Diagnosis and classification of clinical subtypes of ATL
The diagnosis of ATL was based on the following criteria: (1) anti-HTLV-1 positive serum, (2) abnormal PBLs with convoluted or lobulated nuclei or histological findings of ATL in biopsy specimens from the lymph nodes, digestive tract or skin, (3) tumor cells with the mature CD4 þ phenotype and (4) clonal integration of HTLV-1 provirus in the DNA of tumor cells as determined by Southern blotting.
11 ATL was classified into four clinical subtypes, that is, acute-, lymphoma-, chronic-and smoldering type, according to the criteria of the Japanese Lymphoma Study Group.
11
Patients Based on our inclusion criteria, we enrolled 21 ATL patients who had undergone allo-HSCT at Imamura Bun-in Hospital between June 1998 and March 2005. Their median age at the time of allo-HSCT was 49 years (range, 37-62 years). The study population included 18 patients with acute-, 2 with lymphoma-and 1 with chronic-type ATL. Prior informed consent for inclusion in this study was obtained from all patients. Clinical data in their medical records were reviewed and their clinical profiles are summarized in Table 1 .
Response to treatment
Responses to induction chemotherapy and allo-HSCT were evaluated before starting allo-HSCT and at the time when the engraftment was achieved. They were recorded as CR, PR, stable disease (SD) or progressive disease (PD) according to the criteria of the Japan Clinical Oncology Group. CR was defined as the disappearance of all clinical and radiographic evidence of disease and the normalization of lactate dehydrogenase (LDH) for at least 4 weeks. As HTLV-1 carriers frequently harbor a small percentage of abnormal lymphocytes, CR was recorded when less than 5% of such cells were present if the absolute lymphocyte count was less than 4 Â 10 9 per liter. PR was defined as a reduction in measurable disease indices by at least 50% with a more than 75% reduction in the absolute abnormal lymphocyte count for at least 4 weeks without the development of new lesions or disease progression. We also required that LDH was decreased to o1.5 of the normal upper limit. PD was defined by a X25% increase in measurable disease indices or the appearance of new lesions during treatment. Lastly, SD was defined by a response between PR and PD. 5 Conditioning regimen, source of transplanted cells and GVHD prophylaxis The patients underwent conventional myeloablative HSCT (CST) and reduced-intensity HSCT (RIST). Allogeneic stem cells were obtained from bone marrow, peripheral blood or umbilical cord blood.
For GVHD prophylaxis, CYA alone or short-term MTX (sMTX) and CYA were used for HSCT from HLAmatched siblings; for patients received from unrelated-or HLA-mismatched related donors, we used sMTX and CYA or sMTX and tacrolimus.
Assessment of ATL relapse
We evaluated patients with successful HSCT who survived for more than 100 days for ATL relapse or regrowth. In patients who underwent a second transplant because of graft failure or rejection, survival was counted from the first transplant. Relapse was assessed based on the pre-HSCT conditioning regimen, the ATL disease state at/after HSCT and the relapse site.
Diagnosis of GVHD
GVHD was diagnosed based on quantification or histological assessment of skin rash, serum bilirubin, and diarrhea and recorded according to the standard criteria as Grade 0-IV. 12 Donor lymphocyte infusion Donor lymphocyte infusion (DLI) was carried out to induce GVHD in patients who did not show GVHD after the cessation of immunosuppressant therapy because of ATL relapse. CD3 þ lymphocytes (10 7 -10 8 cells per kg) from the peripheral blood of donors were infused.
Immunohistochemical staining
Tissue sections, 4 mm in thickness, were prepared from formalin-fixed, paraffin-embedded specimens. Each section was deparaffinized in xylene; antigenic activity was retrieved by incubation in 0.01 M citrate buffer (pH 6.0) in an autoclave (121 1C, 10 min). The sections were incubated with 3% H 2 O 2 in methanol for 10 min to block endogenous peroxidase activity. Each section was subsequently incubated (room temperature, overnight) with the primary antibody and biotinylated horse anti-mouse immunoglobulin G antibody (Vector Laboratories, Burlingame, CA, USA) diluted 1:200 with Tris. After 30-min reaction with avidin-biotin-peroxidase complex (Vector Laboratories), the samples were incubated for 10 min with diaminobenzidine (brown) (Vector Laboratories) and counterstained with Carrazzi's hematoxylin. The expression of CD4 and 8 was examined in all the cases who suffered skin relapse of ATL or skin GVHD after HSCT 
Statistical analysis
Overall survival (OS) from the day of allo-HSCT was analyzed by the Kaplan-Meier method. The log-rank test was used to compare OS among the subgroups.
Results
Transplant conditions
The ATL disease state at the time of allo-HSCT was CR in seven, PR in one, SD in five and PD in eight patients. Of the 21 patients, 10 underwent CST and 11 received RIST, 5 received a bone marrow transplant, 14 a peripheral blood SCT and 2 a cord blood transplant (Table 1) . Of the four patients who failed or rejected the primary transplant, three underwent a second allo-HSCT procedure.
Response to allo-HSCT Disease state after allo-HSCT was CR in 14, PR in 3, SD in 1 and PD in 3 patients. In 14 patients not in CR at the time of allo-HSCT, 7 patients achieved CR. Survival after allo-HSCT ranged from 1.4 to 83.7 þ months; median survival was 8.4 months. At the time of data collection, seven patients were alive; the median observation period was 28.0 þ months (range, 4.3 þ to 83.7 þ months). The 3-year survival rate of the 21 patients was 33.2±10.9% ( Figure 1) ; it was 12.5% in patients with PD and 47.0% in patients with CR, PR or SD at the time of allo-HSCT. The difference was statistically significant (P ¼ 0.02, Figure 2 ). After allo-HSCT, 15 patients survived for more than 100 days, 7 had undergone RIST and 8 had received CST.
ATL relapse ATL relapsed in 10 of 15 patients who survived more than 100 days (cases 1-10 in Table 2 ) during the administration of immunosuppressants; of these, 6 had undergone RIST and 4 had received CST. With respect to the disease state at allo-HSCT, two patients with CR and eight patients not in CR relapsed. Of these eight patients not in CR at allo-HSCT, four patients achieved CR after allo-HSCT. The site of relapse was the skin in 9, the peripheral blood in 4 and the lymph nodes in 4 patients. In the representative case (case 4), the axillar, supraclavicular and inguinal lymph nodes were enlarged and indurated erythematous plaques appeared on the chest 28 days after HSCT. A biopsy specimen of a chest lesion revealed a Pautrier's microabscess and dense dermal infiltration by lymphoid cells with nuclear atypia. They were positive for CD4 and negative for CD8 (Figure 3 ). We concluded that ATL had relapsed and discontinued the administration of CYA.
Graft-versus-ATL effect
Immunosuppressant therapy for GVHD prophylaxis was discontinued in all 10 patients who suffered a relapse (cases 1-10 in Table 2 ), 8 developed GVHD (grade I, n ¼ 1; grade II, n ¼ 6; grade IV, n ¼ 1). In case 4, within a few days of cessation of CYA administration, the skin lesions disappeared and the lymph node size decreased. After 2 weeks, erythematous plaques reappeared on the trunk. Histologically, these lesions revealed spongiosis, hydropic basal cell degeneration and dermal edema. Infiltrating lymphocytes were predominantly positive for CD8 and the lesion was diagnosed as GVHD ( Figure 4 ). Immunosuppressant therapy was restarted and the patient survived for more than 4 years without ATL relapse. In this case, the cessation of immunosuppressant therapy resulted in the development of acute GVHD which induced the remission of ATL. In six of these eight patients (cases 1-6 in Table 2 ), ATL improved and they ultimately achieved CR. For pre-HSCT conditioning, three patients each had undergone RIST and CST. All six patients suffered ATL relapse in the skin and were monitored closely. One patient (case 4 in Table 2 ) who initially experienced ATL improvement after immunosuppressant therapy was halted and who achieved CR, developed acute skin GVHD. In Graft-versus-adult T-cell leukemia/lymphoma effect K Yonekura et al Abbreviations: ATL ¼ adult T-cell leukemia/lymphoma; CST ¼ conventional myeloablative HSCT, DLI ¼ donor lymphocyte infusion; DT ¼ digestive tract; F ¼ female; Gv-ATL effect ¼ graft-versus-ATL effect; IPD ¼ interstitial pulmonary disease; LN ¼ lymph nodes; M ¼ male; PB ¼ peripheral blood; PD ¼ progressive disease; RIST ¼ reduced-intensity HSCT; SD ¼ stable disease. a Disease status after HSCT was evaluated at the time when the engraftment was achieved. b This patient died after a second ATL relapse in the central nervous system. She achieved CR after the cessation of immunosuppressant therapy administered after the occurrence of a dermal ATL relapse.
cases 1-3, 5, 6 ( Table 2) , biopsy of skin erythema that appeared after immunosuppressant therapy was stopped led to a diagnosis of acute skin GVHD. Their ATL skin lesions improved gradually and they achieved CR with the development of acute skin GVHD. Among two patients, who did not manifest GVHD after the cessation of immunosuppressant therapy, DLI was carried out to induce acute GVHD; one patient (case 9 in Table 2 ) achieved CR.
Discussion
We studied the outcome of allo-HSCT in 21 ATL patients to examine the possible contribution of Gv-ATL effects to its clinical effectiveness. After allo-HSCT, 14 patients achieved CR. The median survival was 8.4 months and the 3-year survival rate was 33.2 ± 10.9%. Our data are comparable to previously reported results. [7] [8] [9] [10] However, we delivered allo-HSCT even in patients whose disease state at HSCT was PD (n ¼ 8) or SD (n ¼ 5); CR was achieved in four of the PD and three of the SD patients, suggesting that even patients with advanced ATL might benefit from allo-HSCT.
We used RIST or CST for pre-HSCT conditioning and found that among 15 patients who survived more than 100 days, 7 had undergone RIST and 8 had received CST. and CST were used in three each. Thus, although the difference between RIST and CST was not significant, we prefer RIST in patients scheduled for allo-HSCT because it is safe and simpler to administer compared to CST.
We carefully examined the clinical course of the 10 patients with relapse who survived more than 100 days. ATL relapsed in two of six patients in status CR at the time of allo-HSCT versus eight of nine who were not in CR at that point. Of these eight patients not in CR at allo-HSCT, four patients achieved CR after allo-HSCT. Not unexpectedly, the incidence of relapse was lower in the patients who were in CR at the time of allo-HSCT. In 9 of 10 patients the skin was the relapse site, suggesting that relapse of ATL after allo-HSCT tends to develop on skin. Uchiyama et al. 1 reported that cutaneous manifestations were seen in at least 50% of ATL patients. Chemokines and their receptors may play a critical role in cellular recruitment and tissue homing and CCR4 and CXCR4 molecules specifically regulate the skin homing of cutaneous T-cell lymphoma cells (CTCL). [13] [14] [15] The expression of molecules responsible for skin homing of ATL cells may be altered after allo-HSCT.
Graft-versus-leukemia effects have been demonstrated after HSCT for other types of leukemia. The minor histocompatibility antigen (mHA) of the recipient is thought to be the target of GVHD; Gv-L or graft-versuslymphoma (Gv-Ly) effects are mediated by mHA on the recipient leukemia cells. 16 The likelihood of leukemia recurrence after allo-HSCT was increased when the T cells were removed from the graft or the donor was a genetically identical twin, 17 indicating that Gv-L effects play an important role in the prevention of leukemia recurrence. We discontinued immunosuppressant therapy in 10 patients with ATL relapse because we suspected the involvement of Gv-ATL effects. GVHD developed in eight patients and ATL was ameliorated to CR in six of these eight patients. The other two patients received DLI to induce GVHD; one patient obtained CR. These results demonstrate that Gv-ATL effects played a critical role in eradicating the ATL lesions. While the Gv-ATL effects are beneficial in the treatment of ATL, possible toxicity of the procedure should be concerned in the clinical settings because 9 of 21 patients died of GVHD or thrombotic microangiopathy in this study.
In our study population, ATL relapsed on the skin of 9 of 10 patients. Others [18] [19] [20] [21] reported Gv-Ly effects in CTCL. Our review of the literature uncovered 21 CTCL patients who underwent allo-HSCT, 11 had mycosis fungoides and 10 had Se´zary syndrome; 18-26 6 suffered relapse and 1 patient each achieved CR and PR after the cessation of immunosuppressant therapy. The Gv-ATL effects noted in our study appear to be more profound than those reported in the literature. In five patients with ATL relapse on the skin alone (Table 2) , four patients achieved CR after acute GVHD following the discontinuation of the immunosuppressants. Since skin is one of the major target organs of acute GVH reaction, 27 Gv-ATL effect might be more significant in patients with skin relapse alone.
Although the number is limited, our retrospective study demonstrated the Gv-ATL effects of allo-HSCT particularly in patients with skin lesions. Studies are underway in our laboratory to determine the optimal conditions for allo-HSCT in patients with ATL.
